Semaglutide selectively activates the GLP-1 receptor, producing: Glucose-dependent insulin secretion : Reduces hypoglycemia risk compared to non-incretin agents Glucagon suppression : Reduces hepatic glucose output in the hyperglycemic state Gastric emptying delay : Contributes to postprandial glucose control and satiety Central appetite regulation : Acts on GLP-1 receptors in the hypothalamus and brainstem to reduce hunger and alter food preferences The simplicity of semaglutide's single-receptor mechanism is both a limitation (no energy expenditure enhancement from glucagon) and a strength (thoroughly understood pharmacology, predictable effects, extensive safety characterization)
Many experience increased hunger, the return of "food noise," changes in blood sugar control and the loss of some cardiometabolic benefits, while side effects like nausea and constipation often improve
The Easy Way Out and Other Misconceptions Despite strong evidence, these medications are often judged harshlyseen as a shortcut or cosmetic fix
Ali AM, Martinez R, Al-Jobori H, Adams J, Triplitt C, DeFronzo R, et al
A small note on air bubble anxiety: subcutaneous air bubbles are not dangerous
Ageing Res
